Market News
2 min read | Updated on December 12, 2024, 14:00 IST
SUMMARY
Sai Life Sciences IPO: The ₹3042.62 crore initial share sale, with a price range of ₹522-₹549 a unit, is a mix of fresh issuance of equity shares aggregating ₹950 crore and an offer-for-sale of ₹2,092 crore.
Sai Life Sciences IPO will conclude on December 13.
Sai Life Sciences IPO: The initial public offer of Sai Life Sciences has been fully subscribed on the second day of bidding on Thursday, December 12.
The initial share sale received bids for 3,91,28,724 shares against 3,88,29,848 equity shares on offer, taking the total subscription to 1.01 times till 2 pm.
Prior to the IPO, Sai Life Sciences, which is backed by TPG Capital, collected ₹913 crore from anchor investors, including Fidelity Funds, INQ Holding LLC, Goldman Sachs Funds, SmallCap World Fund Inc, BlackRock, Abu Dhabi Investment Authority, Nippon India Mutual Fund (MF), Kotak Mahindra MF, Axis MF and HDFC MF.
The ₹3042.62 crore IPO, with a price range of ₹522-₹549 a unit, is a mix of fresh issuance of equity shares aggregating ₹950 crore and an offer-for-sale of ₹2,092 crore.
Under the OFS, Sai Quest Syn Pvt Ltd, a promoter entity, and investor shareholders HBM Private Equity India and TPG Asia VII SF Pte Ltd will partly divest their respective stakes.
The money raised will be used to pay off debt and serve general corporate purposes.
An interested investor can bid for at least 20 shares, requiring an investment of ₹14,823.
Investor Category | Shares Offered |
---|---|
Anchor Investors | 30% |
QIBs | 20% |
NIIs | 15% |
Retail investors | 35% |
Total | 100% |
Hyderabad-based Sai Life Sciences is an end-to-end services provider across the drug discovery and manufacturing value chain for small molecule new chemical entities to global pharmaceutical innovator firms and biotechnology companies.
About The Author
Next Story